RESAPHENE SUISSE AG Resaphene Suisse AG: European Patent Office announces patent for tinnitus therapy

Transparency directive : regulatory news

07/12/2018 21:54




DGAP-Ad-hoc: Resaphene Suisse AG / Key word(s): Patent


Resaphene Suisse AG: European Patent Office announces patent for tinnitus therapy (news with additional features)


07-Dec-2018 / 21:54 CET/CEST


Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.


The issuer is solely responsible for the content of this announcement.




Roggwil, December 7, 2018 - Resaphene Suisse AG, ISIN CH0367465439, WKN A2JG91, has been informed of the announcement of patent grant by the European Patent Office. In a novel procedure involving a combination of Tailor Made-Notched Music Training (TMNMT) and heat therapy, an initial clinical user observation showed an average relief of 54% within 4 weeks in patients with chronic subjective tonal decompensated tinnitus; in individual cases, a decrease of 100 percent (complete disappearance) was noted.

 

"We identified the heatable in-ear headphones we developed as the key to successful therapy. The next step is an extensive double-blind placebo-controlled study at a large university hospital, "says Anke Rauterkus, CEO of Resaphene Suisse AG.

 

As part of the highly complex procedure, the project management for patenting was replaced by a long-term experienced project manager by the Board of Directors. This led to a significant shortening of the process. The Board is now expecting the swift completion of the US patent application.

 

++ About Resaphene Suisse AG

 

Resaphene Suisse AG, based in Roggwil, Switzerland, is a medical technology company founded in 2015 and since 2016 sold under the name Tinniwell a tinnitus therapy device. Since June 2018, the shares have been traded on the Vienna Stock Exchange in the Third Market segment. As another distribution companies are the Resaphene Deutschland GmbH in Konstanz and the Resaphene UK Ltd. in London.

 

++ Contact for further questions:

 

Resaphene Suisse AG

Rütistrasse 8b

9325 Roggwil

Switzerland

 

Investor Relations Contact:

Mr. Thomas Rauterkus (Chief Financial Officer)

t.rauterkus@resaphene.ch




Additional features:

Picture: http://newsfeed2.eqs.com/resaphene/755797.html
Subtitle: Tinniwell


07-Dec-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de





















Language: English
Company: Resaphene Suisse AG

Rütistrasse 8b

9325 Roggwil

Switzerland
Phone: 0041714500668
E-mail: info@resaphene.ch
Internet: www.resaphene.ch
ISIN: CH0367465439
Listed: Foreign Exchange(s) Vienna Stock Exchange





 
End of Announcement DGAP News Service




755797  07-Dec-2018 CET/CEST







fncls.ssp?fn=show_t_gif&application_id=755797&application_name=news&site_id=symex

RESAPHENE SUISSE AG's latest news


07/12/2018 21:54


Other stories

11/12/2018 19:14
12/12/2018 00:47
12/12/2018 00:57
11/12/2018 20:11
11/12/2018 19:45
11/12/2018 17:27
12/12/2018 01:01
11/12/2018 09:47
11/12/2018 23:00
11/12/2018 23:57
11/12/2018 21:23
11/12/2018 08:21
11/12/2018 21:58
11/12/2018 13:36
11/12/2018 16:58
10/12/2018 18:50
11/12/2018 20:37
11/12/2018 12:30
11/12/2018 22:34
11/12/2018 15:48
11/12/2018 21:20
11/12/2018 21:51
11/12/2018 12:11
12/12/2018 01:01
11/12/2018 23:54
11/12/2018 23:09
11/12/2018 20:17
11/12/2018 23:30
11/12/2018 18:20
11/12/2018 13:59
11/12/2018 01:01
11/12/2018 11:19
11/12/2018 11:45
11/12/2018 12:50
11/12/2018 19:46
11/12/2018 16:41